Dr. Chris Penton is currently Head of High Throughput Screening and Assay Development at the ACDD. Chris has more than eight years of industry drug discovery experience at Sanofi, Icagen, and Recursion.

One of Chris’s favorite projects involved designing and establishing a high-throughput cellular assay for a two million compound screen at Icagen in Oro Valley, AZ. This novel screen used a hybrid enhancer and promoter-regulating full-length gene reporter on a premature termination codon target. As a result of the project, Chris developed more than twenty-five cell lines using Transposon and Lentiviral systems. Chris also designed and developed multiple reporter assays using the NanoBiT system, the HiBiT system, NanoLuc and other luciferases. At Recursion, Chris used 1536-well automated Cell Painting for high-content imaging. He loves transfections and also helped optimize 1536-well CRISPR guide RNA transfection protocols to increase performance and efficiency.

He enjoys the fast pace of drug discovery, the inherent nuances, and the challenges of combining multiple systems to capture as much biology and data as possible from each assay.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.